- Home
- QTTB
QTTB
Q32 Bio Inc. Common Stock
as 04-18-2025 1:42pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $24.00 | AVG Volume (30 days): | 175.3K |
| Analyst Decision: | Hold | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $53.79 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Q32 Bio Inc. Common Stock News
QTTB Breaking Stock News: Dive into QTTB Ticker-Specific Updates for Smart Investing
PR Newswire
3 days ago
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
PR Newswire
a month ago
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
a month ago
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
PR Newswire
2 months ago
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
PR Newswire
2 months ago
Q32 Bio to Participate in Upcoming March Investor Conferences
PR Newswire
2 months ago
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
PR Newswire
2 months ago
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
TipRanks
4 months ago
Q32 Bio price target lowered to $20 from $80 at Oppenheimer
Compare QTTB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QTTB Q32 Bio Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.